Media coverage about Novartis (NYSE:NVS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.8729285199226 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s analysis:
- Keep an eye on Analysts Rating: Novartis AG (NVS) – Wall Street Morning (wallstreetmorning.com)
- Novartis AG (NVS) Stock Price trades -2.61% off from 200- SMA – Nasdaq Chronicle (nasdaqchronicle.com)
- Early Moves to Watch – Novartis AG (NYSE: NVS) – Stocks Pen (stockspen.com)
- Is The Stock Worthy? – Novartis AG (NYSE: NVS) – Alpha Beta Stock (alphabetastock.com)
- Swiss Pharma Gets a Taste of Silicon Valley (finance.yahoo.com)
A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. UBS reaffirmed a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $87.51.
Shares of Novartis (NVS) traded up $0.25 during mid-day trading on Friday, reaching $82.06. 1,987,948 shares of the company were exchanged, compared to its average volume of 1,675,672. Novartis has a fifty-two week low of $72.67 and a fifty-two week high of $94.19. The company has a market capitalization of $190,587.58, a price-to-earnings ratio of 25.25, a P/E/G ratio of 1.91 and a beta of 0.78. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91.
Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.04. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The firm had revenue of $12.92 billion for the quarter, compared to the consensus estimate of $12.65 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. equities analysts anticipate that Novartis will post 5.36 EPS for the current fiscal year.
WARNING: “Novartis (NVS) Earns Daily News Sentiment Score of 0.19” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://ledgergazette.com/2018/03/16/novartis-nvs-earns-daily-news-sentiment-score-of-0-19.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.